MedTrace Logo

Effect of Probenecid on Synovial Fluid ATP Levels in CPPD

NCT02243631 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-07-26

Study results available
· View outcomes & findings →

Summary

This study will investigate the hypothesis that probenecid, a medication currently used for gout, reduces levels of ATP in the joint fluid of patients with calcium pyrophosphate deposition disease (CPPD), another common type of crystal-related arthritis. There is good evidence that CPPD results from an excess of ATP in joints. The investigators will measure levels of ATP in joint fluid before and after 5 days of treatment with probenecid. This study will serve to rationalize larger studies of probenecid in CPPD.

Conditions

  • Calcium Pyrophosphate Deposition Disease

Interventions

DRUG

Probenecid

Treatment

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Ann K Rosenthal, MD · Clement J. Zablocki VA Medical Center, Milwaukee, WI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-15
Primary Completion
2021-04-08
Completion
2021-04-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02243631 on ClinicalTrials.gov